Patents by Inventor Simon Nicolas Haydar

Simon Nicolas Haydar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20240025890
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: William W. TURNER, Lee D. ARNOLD, Hans MAAG, Leping LI, Mark G. BURES, Simon Nicolas HAYDAR, Samson FRANCIS
  • Hepatitis b core protein modulators
    Patent number: 11814376
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: November 14, 2023
    Assignees: Assembly Biosciences, Inc., Indiana University Research and Technology Corporation
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV
    Publication number: 20230295096
    Abstract: The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: April 21, 2021
    Publication date: September 21, 2023
    Inventors: Simon Nicolas HAYDAR, Thilo HECKRODT, Michael WALKER, Min ZHONG
  • CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV
    Publication number: 20230075856
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: September 5, 2019
    Publication date: March 9, 2023
    Inventors: Michael Walker, Leping Li, Simon Nicolas Haydar
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20230044112
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 4, 2021
    Publication date: February 9, 2023
    Applicants: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • 5-membered heteroaryl carboxamide compounds for treatment of HBV
    Patent number: 11560370
    Abstract: The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: January 24, 2023
    Assignee: Assembly Biosciences, Inc.
    Inventors: Simon Nicolas Haydar, Leping Li, Mark G. Bures, Roopa Rai, Lynne Bannen, Michael Walker
  • CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20230012463
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: January 14, 2021
    Publication date: January 12, 2023
    Inventors: William W. Turner, Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV
    Publication number: 20220081433
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: September 5, 2019
    Publication date: March 17, 2022
    Inventors: Michael Walker, Leping Li, Simon Nicolas Haydar
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20220023311
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: January 14, 2021
    Publication date: January 27, 2022
    Inventors: William W. Turner, Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Cyclic sulfamide compounds and methods of using same
    Patent number: 11078170
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 3, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • Hepatitis B core protein modulators
    Patent number: 10987360
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 27, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Hepatitis B core protein modulators
    Patent number: 10968211
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: April 6, 2021
    Assignees: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20200157070
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: March 1, 2018
    Publication date: May 21, 2020
    Inventors: William W. Turner, JR., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20200131168
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 30, 2020
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20190255067
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 22, 2019
    Inventors: William W. Turner, JR., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 8063053
    Abstract: The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: November 22, 2011
    Assignee: Wyeth LLC
    Inventors: Simon Nicolas Haydar, Patrick Michael Andrae, Heedong Yun, Albert Jean Robichaud
  • Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7939520
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: May 10, 2011
    Assignee: Wyeth LLC
    Inventors: Simon Nicolas Haydar, Patrick Andrae
  • 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20100120779
    Abstract: The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Application
    Filed: November 11, 2009
    Publication date: May 13, 2010
    Applicant: Wyeth
    Inventors: Simon Nicolas Haydar, Patrick Michael Andrae, Heedong Yun, Albert Jean Robichaud
  • AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20080293688
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: May 13, 2008
    Publication date: November 27, 2008
    Applicant: Wyeth
    Inventors: Simon Nicolas Haydar, Patrick Andrae